TrialCancer immunology, immunotherapy : CII2012

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.

Osama E Rahma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.